Marine and Soil Derived Natural Products: A New Source of Novel Cardiovascular Protective Agents Targeting the Endothelin System

Abstract

Inhibition of the endothelin system is a recognized therapeutic approach for treating complex cardiovascular diseases. The search for natural inhibitors of the endothelin system has focused mainly on land, with recent, emerging data suggesting the underestimated potential of marine microorganisms for producing leads with cardioprotective potential. The present work reviews natural products identified as inhibitors of the endothelin system, their origin, their mechanism of action, and their ecological significance.

Key words

endothelin - hypertension - cardiovascular - marine natural products - microorganisms - ecology

• References

• 1 Skropeta D, Wei L. Recent advances in deep-sea natural products. Nat Prod Rep 2014; 31: 999-1025
• 2 Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep 2014; 31: 160-258
• 3 Abad MJ, Bedoya LM, Bermejo P. Natural marine anti-inflammatory products. Mini Rev Med Chem 2008; 8: 740-754
• 4 König G, Wright AD. Marine natural products research: current directions and future potential. Planta Med 1996; 62: 193-211
• 5 Mayer AM, Hamann MT. Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2002; 132: 315-339
• 6 Mayer AM, Rodríguez AD, Taglialatela-Scafati O, Fusetani N. Marine pharmacology in 2009–2011: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar Drugs 2013; 1: 2510-2573
• 7 von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014; 144: 41-49
• 8 Nasser SA, El-Mas MM. Endothelin ET_A receptor antagonism in cardiovascular disease. Eur J Pharmacol 2014; 15: 210-213
• 9 Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 2014; 8: 202-216
• 10 Novo G, Sansone A, Rizzo M, Guarneri FP, Pernice C, Novo S. High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study. J Cardiovasc Med (Hagerstown) 2014; 15: 696-701
• 11 Wijesekara I, Kim SK. Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry. Mar Drugs 2010; 18: 1080-1093
• 12 Gulavita NK, Wright AE, McCarthy PJ, Pomponi SA, Kelly-Borges M, Chin M, Sills MA. Isolation and structure elucidation of 34-sulfatobastadin 13, an inhibitor of the endothelin A receptor, from a marine sponge of the genus Ianthella . J Nat Prod 1993; 56: 1613-1617
• 13 Pairet L, Wrigley SK, Chetland I, Reynolds EE, Hayes MA, Holloway J, Ainsworth AM, Katzer W, Cheng XM, Hupe DJ. Azaphilones with endothelin receptor binding activity produced by Penicillium sclerotiorum: taxonomy, fermentation, isolation, structure elucidation and biological activity. J Antibiot (Tokyo) 1995; 48: 913-923
• 14 Caballero-George C, Sorkalla T, Jakobs D, Bolaños J, Raja H, Shearer C, Bermingham E, Häberlein H. Fluorescence correlation spectroscopy in drug discovery: study of Alexa532-endothelin 1 binding to the endothelin ET_A receptor to describe the pharmacological profile of natural products. Sci World J 2012; 2012: 524169
• 15 Caballero-George C. Does nature has the cure for hypertension?: Endothelin Receptors as Drug Targets. Curr Trends Biotechnol Pharm 2011; 5: 1251-1272
• 16 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
• 17 Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. FASEB J 1990; 4: 2989-3000
• 18 Rabelink TJ, Stroes ES, Bouter KP, Morrison P. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease. Cardiovasc Res 1998; 39: 543-549
• 19 Tirapelli CR, Fecteau MH, Honore JC, Legros E, Gobeil F, DʼOrleans-Juste P. Enzymatic pathways involved in the generation of endothelin-1(1–31) from exogenous big endothelin-1 in the rabbit aorta. Br J Pharmacol 2006; 148: 527-535
• 20 Casey ML, Word RA, MacDonald PC. Endothelin-1 gene expression and regulation of endothelin mRNA and protein biosynthesis in a vascular human amnion. Potential source of amniotic fluid endothelin. J Biol Chem 1991; 266: 5762-5768
• 21 Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002; 3: 1-15
• 22 Holzhauser L, Zolty R. Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. Heart Fail Rev 2014; 19: 743-758
• 23 Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012; 84: 147-162
• 24 Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house. Br J Pharmacol 2008; 153: 1105-1119
• 25 Moorhouse RC, Webb DJ, Kluth DC, Dhaun N. Endothelin antagonism and its role in the treatment of hypertension. Curr Hypertens Rep 2013; 15: 489-496
• 26 Gray GA, Webb D. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996; 72: 109-148
• 27 McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the pressor activity of big endothelin[1–39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17: 29-33
• 28 Martínez-Miguel P, Medrano-Andrés D, Lopes-Martín V, Arribas-Gómez I, Rodríguez-Puyol M, Rodríguez-Puyol D, López-Ongil S. Regulation of endothelin-converting enzyme-1 (ECE-1) by the calcimimetic R-568. Pharmacol Res 2013; 76: 106-118
• 29 Habib GB, Basra SS. Are there any new pharmacologic therapies on the horizon to better treat hypertension: a state-of-the-art paper. J Cardiovasc Pharmacol Ther 2014; 19: 516-525
• 30 Strachan E, Spratt C, Wilkinson B, Johnston R, Gray G, Webb J. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999; 33: 581-585
• 31 Nakamura H, Kobayashi J, Kobayashi M, Ohizumi Y, Hirata Y. Xestoquinone. A novel cardiotonic marine natural product isolated from the Okinawan sea sponge Xestospongia sapra . Chem Letters 1985; 6: 713-716
• 32 Zhu HB, Geng MY, Guan HS, Zhang JT. Antihypertensive effects of D-polymannuronic sulfate and its related mechanisms in renovascular hypertensive rats. Acta Pharmacol Sin 2000; 21: 727-732
• 33 Endo M, Nakagawa W, Hamamoto Y, Ishihama M. Pharmacologically active substances from southern pacific marine invertebrates. Pure Appl Chem 1986; 58: 387-394
• 34 Kaul PN. Biomedical potencial of the sea. Pure Appl Chem 1982; 54: 1963-1972
• 35 Anastasi A, Erspamer V. The isolation and amino acid sequence of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone . Arch Biochem Biophys 1963; 101: 56-65
• 36 Ihara M, Fukuroda T, Saeki T, Nishikibe M, Kojiri K, Suda H, Yano M. An endothelin receptor (ET_A) antagonist isolated from Streptomyces misakiensis . Biochem Biophys Res Commun 1991; 178: 132-137
• 37 Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T, Suda H, Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 1992; 20 (Suppl. 12) S11-S14
• 38 Miyata S, Ohhata N, Murai H, Masui Y, Ezaki M, Takase S, Nishikawa M, Kiyoto S, Okuhara M, Kohsaka M. WS009 A and B, new endothelin receptor antagonists isolated from Streptomyces sp. No. 89009. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 1992; 45: 1029-1040
• 39 Takaishi S, Tuchiya N, Sato A, Negishi T, Takamatsu Y, Matsushita Y, Watanabe T, Iijima Y, Haruyama H, Kinoshita T, Tanaka M, Kodama K. B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J Antibiot (Tokyo) 1998; 51: 805-815
• 40 Tsurumi Y, Fujie K, Nishikawa M, Kiyoto S, Okuhara M. Biological and pharmacological properties of highly selective new endothelin converting enzyme inhibitor WS79089B isolated from Streptosporangium roseum No. 79089. J Antibiot (Tokyo) 1995; 48: 169-174
• 41 Nakamura M, Ito Y, Ogawa K, Michisuji Y, Sato S, Takada M, Hayashi M, Yaginuma S, Yamamoto S. Stachybocins, novel endothelin receptor antagonists, produced by Stachybotrys sp. M6222. I. Taxonomy, fermentation, isolation and characterization. J Antibiot (Tokyo) 1995; 48: 1389-1395
• 42 Wu B, Oesker V, Wiese J, Malien S, Schmaljohann R, Imhoff JF. Spirocyclic drimanes from the marine fungus Stachybotrys sp. strain MF347. Mar Drugs 2014; 12: 1924-1938
• 43 Zhou H, Zhu T, Cai S, Gu Q, Li D. Drimane sesquiterpenoids from the mangrove-derived fungus Aspergillus ustus . Chem Pharm Bull (Tokyo) 2011; 59: 762-766
• 44 Liu H, Edrada-Ebel R, Ebel R, Wang Y, Schulz B, Draeger S, Müller WE, Wray V, Lin W, Proksch P. Drimane sesquiterpenoids from the fungus Aspergillus ustus isolated from the marine sponge Suberites domuncula . J Nat Prod 2009; 72: 1585-1588
• 45 Roggo BE, Petersen F, Sills M, Roesel JL, Moerker T, Peter HH. Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by Stachybotrys sp. I. Fermentation, isolation and biological activity. J Antibiot (Tokyo) 1996; 49: 13-19
• 46 Ogawa T, Ando K, Tanaka T, Uosaki Y, Matsuda Y. RES-1149-1 and − 2, novel non-peptidic endothelin type B receptor antagonists produced by Aspergillus sp. I. Taxonomy of producing strain, fermentation, isolation, and physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 1-5
• 47 Hayes MA, Wrigley SK, Chetland I, Reynolds EE, Ainsworth AM, Renno DV, Latif MA, Cheng XM, Hupe DJ, Charlton P, Doherty AM. Novel drimane sesquiterpene esters from Aspergillus ustus var. pseudodeflectus with endothelin receptor binding activity. J Antibiot (Tokyo) 1996; 49: 505-512
• 48 Li J, Yang X, Lin Y, Yuan J, Lu Y, Zhu X, Li J, Li M, Lin Y, He J, Liu L. Meroterpenes and azaphilones from marine mangrove endophytic fungus Penicillium 303#. Fitoterapia 2014; 97: 241-246
• 49 Yamada T, Jinno M, Kikuchi T, Kajimoto T, Numata A, Tanaka R. Three new azaphilones produced by a marine fish-derived Chaetomium globosum . J Antibiot (Tokyo) 2012; 65: 413-417
• 50 Gao SS, Li XM, Zhang Y, Li CS, Cui CM, Wang BG. Comazaphilones A–F, azaphilone derivatives from the marine sediment-derived fungus Penicillium commune QSD-17. J Nat Prod 2011; 74: 256-261
• 51 Ogawa T, Ando K, Aotani Y, Shinoda K, Tanaka T, Tsukuda E, Yoshida M, Matsuda Y. RES-1214-1 and -2, novel non-peptidic endothelin type A receptor antagonists produced by Pestalotiopsis sp . J Antibiot (Tokyo) 1995; 48: 1401-1406
• 52 Proksch P, Ebel R, Edrada RA, Wray V, Steube K. Bioactive natural products from marine invertebrates and associated fungi. Prog Mol Subcell Biol 2003; 37: 117-142
• 53 Patil A, Freyer A, Breen A, Carte B, Johnson R. Halistanol disulfate B, a novel sulfate sterol from sponge Pachastrella sp.: inhibitor of endothelin converting enzyme. J Nat Prod 1996; 59: 606-608
• 54 Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat Chem Biol 2007; 3: 408-414
• 55 Latek D, Modzelewska A, Trzaskowski B, Palczewski K, Filipek S. G protein-coupled receptors-recent advances. Acta Biochim Pol 2012; 59: 515-529
• 56 Pin JP, Galvez T, Prézeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003; 98: 325-354
• 57 Senni K, Pereira J, Gueniche F, Delbarre-Ladrat C, Sinquin C, Ratiskol J, Godeau G, Fischer AM, Helley D, Colliec-Jouault S. Marine polysaccharides: a source of bioactive molecules for cell therapy and tissue engineering. Mar Drugs 2011; 9: 1664-1681
• 58 Conibear AC, Craik DJ. The chemistry and biology of theta defensins. Angew Chem Int Ed Engl 2014; 53: 10612-10623
• 59 Sjögren M, Jonsson PR, Dahlström M, Lundälv T, Burman R, Göransson U, Bohlin L. Two brominated cyclic dipeptides released by the coldwater marine sponge Geodia barretti act in synergy as chemical defense. J Nat Prod 2011; 74: 449-454
• 60 Xiong Z, Wang J, Hao J, Wang Y. Recent advances in the discovery and development of marine microbial natural products. Mar Drugs 2013; 11: 700-717